136 related articles for article (PubMed ID: 37991858)
1. Scleromyxedema.
Chatterjee S; Fernandez AP
N Engl J Med; 2023 Nov; 389(21):1992. PubMed ID: 37991858
[No Abstract] [Full Text] [Related]
2. Clinical features of scleromyxoedema in an Afro-Caribbean man.
Ufodiama CE; Tynes G; Unwala R
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30665930
[No Abstract] [Full Text] [Related]
3. Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e213-5. PubMed ID: 25065780
[No Abstract] [Full Text] [Related]
4. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
5. [Scleromyxedema with neurological symptoms: successful treatment with immunoglobulins].
Manríquez J; Berroeta-Mauriziano D; Andino-Navarrete R; Vera-Kellet C
Med Clin (Barc); 2015 Jan; 144(1):47-8. PubMed ID: 24656121
[No Abstract] [Full Text] [Related]
6. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema.
Binitha MP; Nandakumar G; Thomas D
Indian J Dermatol Venereol Leprol; 2008; 74(3):248-50. PubMed ID: 18583794
[TBL] [Abstract][Full Text] [Related]
7. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
8. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxedema and Hyperphosphatemia: Causal Relationship or Coincidence?
Mousavi S; Masoumi M; Shakiba S
J Clin Rheumatol; 2021 Aug; 27(5):e160-e161. PubMed ID: 32028300
[No Abstract] [Full Text] [Related]
10. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
11. Treatment of scleromyxedema with intravenous immunoglobulin.
Roque Diamantino Fde E; Lopes João AM; Clemente Fidalgo AI; Taveira Lobo Mde L
Eur J Dermatol; 2010; 20(6):861-2. PubMed ID: 20956104
[No Abstract] [Full Text] [Related]
12. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
14. Fever, Joint Pain, Seizures, and Rash in a 53-Year-Old Woman.
Weiner J; Marano A; Cardones A; Criscione-Schreiber L
Arthritis Care Res (Hoboken); 2017 Sep; 69(9):1437-1443. PubMed ID: 28376294
[No Abstract] [Full Text] [Related]
15. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years.
Devos T; Thiessen S; Cuyle PJ; Meersseman W; Delforge M
Ann Hematol; 2014 Nov; 93(11):1927-8. PubMed ID: 24676971
[No Abstract] [Full Text] [Related]
17. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
18. Dermato-neuro syndrome after COVID-19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins.
Li Y; Wang H; Wang A; Zhao G
J Dermatol; 2024 Jan; 51(1):140-144. PubMed ID: 37830263
[TBL] [Abstract][Full Text] [Related]
19. [Scleromyxedema. A chronic progressive systemic disease].
Kreuter A; Stücker M; Kolios AG; Altmeyer P; Möllenhoff K
Z Rheumatol; 2012 Aug; 71(6):504-14. PubMed ID: 22806700
[TBL] [Abstract][Full Text] [Related]
20. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
